Evidence map›Paper›PMID 41583511›Full record

ArticleInternational journal of medical sciences2026

Missense and Intronic Variants in

Min-Che Tung, Yung-Wei Lin, Chung-Howe Lai, Chia-Yen Lin, Lun-Ching Chang, Yu-Ching Wen, Shun-Fa Yang, Ming-Hsien Chien

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min-Che TungDivision of Urology, Department of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan.
Yung-Wei LinInternational Master/PhD Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chung-Howe LaiGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Chia-Yen LinDivision of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.
Lun-Ching ChangDepartment of Mathematics and Statistics, Florida Atlantic University, Boca Raton, Florida, United States.
Yu-Ching WenDepartment of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Shun-Fa YangInstitute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Ming-Hsien ChienGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is a genetically and phenotypically heterogeneous disease, and further advancements in PCa biomarker discovery are urgently required. Hepatocyte nuclear factor 1 A (HNF1A), a transcription factor, plays a critical role in PCa progression after biochemical recurrence (BCR). However, studies investigating the impact of

Indexed as

Hepatocyte Nuclear Factor 1-alphaNeoplasm Recurrence, LocalProstatic NeoplasmsAgedBiomarkers, TumorDisease ProgressionGenetic Predisposition to DiseaseHumansIntronsMaleMiddle AgedMutation, MissenseNeoplasm GradingPolymorphism, Single NucleotideProstateTaiwanBiomarkers, TumorHepatocyte Nuclear Factor 1-alphaHNF1A protein, humanbiochemical recurrenceclinicopathologic progressionhepatocyte nuclear factor 1 alphaprostate cancersingle-nucleotide polymorphism

Identifiers

PMID41583511
PMCPMC12825144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.